Coronary Drug Eluting Stent Market

Coronary Drug Eluting Stent Market, Distribution by Type of Drug Eluted, Stent Material and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    0

  • Pages
    254

  • View Count
    10832

Coronary Drug Eluting Stent Market Overview

The coronary drug eluting stent market is estimated to be worth $3.8 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 9.26% during the forecast period. Cardiovascular diseases (CVD) are reported to be one of the leading causes of deaths across the globe, surpassing conditions, such as cancer and respiratory disorders.  According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders.  Specifically, coronary artery disease (CAD) is the most common form of cardiovascular disorder; around 11 million deaths were linked to this indication in 2020. It is worth mentioning that, in 2020 (post the onset of the pandemic), a more than 3% increase in the deaths related to heart diseases was reported. Further, according to the Centers for Disease Control and Prevention, the financial burden (in terms of annual medical costs and loss of productivity) associated with cardio vascular diseases is expected to be surpass USD 1,000 billion, in 2030.  In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; coronary drug eluting stent (DES) / cardiac stent have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stent (BMS) was used extensively to open the blocked passages and restore adequate blood flow to the heart. In recent years, a shift in preference has been observed towards the use of drug-eluting stent (DES), which are coated with a polymer carrying an antiproliferative drug. Such cardiac stents have been demonstrated to reduce / prevent in-stent restenosis (re-narrowing of the arteries previously opened using angioplasty), which was a major complication associated with the use of bare-metal stents. Cardiac stents are considered to be revolutionary in the interventional cardiology domain, as they enable improved revascularization rates and reduced risk of thrombosis.

Presently, over 90 cardiovascular drug eluting stents are being offered by around 40 players located across the globe. Majority of such devices employ the use of metals, such as platinum chromium and stainless steel. Further, the patents focused on cardiovascular drug eluting stents and associated technologies have been filed / granted at a CAGR of 13%, in the past two decades. In this context, it is important to note that, over the past few years, there have been significant innovations in cardiovascular therapeutics domain, in terms of development of advanced bioresorbable stents, drug combinations, polymer and nanomaterial coatings, to further increase the safety and efficacy of these treatment options. For instance, recently, an implantable biocompatible stent containing miniaturized ultrasonic transducers have been proposed by a group of researchers, which can be used for real-time monitoring of restenosis in the patients. Moreover, recent advancements related to the use of augmented reality and deep learning can enable the development of patient-specific stents, paving the way for personalized-treatment for patients suffering from cardiovascular disorders. Given the ongoing pace of innovation in coronary drug eluting stent market, adoption of cutting-edge technologies by device developers, the ever-increasing incidence of heart diseases and the rise in demand for associated treatments, we believe that the cardiovascular drug eluting stent market is likely to witness a significant market growth during the forecast period.

This image highlights context of Novel Cardiovascular Drug Delivery Market report. Owing to the potential of drug eluting stents to treat a range of cardiovascular disorders (CVDs), as well as their ability to circumvent complications associated with the use of bare metal stents, such devices have generated significant interest within the healthcare domain This image provides list of Companies Offering Drug Eluting Stents. At present, more than 90 cardiovascular drug eluting stents, coated with various types of anti proliferative drugs, are being offered by players located across the globe This image presents current market landscape of Novel Cardiovascular Drug Delivery Devices Market. Majority of the devices, designed to elute a range of drugs, use cobalt alloys as a coating material; interestingly, a large proportion of the total stents are being manufactured by players based in developing nations

Key Companies in Coronary Drug Eluting Stent Market 

Examples of key companies engaged in coronary drug eluting stent market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alvimedica, B. Braun, Boston Scientific, Cook Medical, Eurocor Scientific, Lepu Medical, Medtronic, Meril, Relisys and Sahajanand Medical Technologies. This coronary drug eluting stent market report includes an easily searchable excel database of all the companies providing drug eluting stent for cardiovascular disorders, worldwide.

Recent Developments in Coronary Drug Eluting Stent Market:

Several recent developments have taken place in the field of cardiac stent market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Surmodics’ SurVeil™ drug-coated balloon received premarket approval from the US FDA. The device is coated with Surmodic’s proprietary drug-excipient formula, targeted for the treatment of peripheral artery disease (PAD).  
  • In July 2023, the US FDA removed all restrictions from the use of paclitaxel coated drug delivery devices for the treatment of peripheral artery disease (PAD). 
  • In May 2023, Concept Medical’s proprietary Magic Touch SCB (Sirolimus Coated Balloon) received the third investigational device exemption approval (IDE) from the US FDA for the treatment of small vessels (SV) in coronary arteries.

Scope of the Report

The “Coronary Drug Eluting Stent Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in cardiovascular drug eluting stent market. The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space.

This image highlights competitive analysis of players engaged in the domain of Novel Cardiovascular Drug Delivery. In order to gain an edge in this competitive industry, companies are continuously upgrading their devices to enrich their existing portfolio This image provides information on patents that have been filed / granted related to cardiovascular drug eluting stents. Over 900 patents have been filed / granted for cardiovascular drug eluting stents; both industry and non-industry players are actively involved in such efforts This image presents market trends of Novel Cardiovascular Therapeutics and Services. Gene therapies and subcutaneous biologics represent over 90% of the therapies being evaluated to treat cardiovascular disorders; several players are offering services to support such development initiatives

Amongst other elements, the market report includes:

  • A detailed overview of the current market landscape of the players engaged in developing / manufacturing cardiovascular drug eluting stents, including information on their respective year of establishment, company size (in terms of number of employees), number of products offered and location of headquarters. Further, it provides a detailed assessment of the overall landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of eluted drug, type of cardiac stent material, post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.
  • An in-depth analysis, highlighting the contemporary market trends, using five schematic representations, including a heat map representation (based on type of drug eluted and administered drug concentration), a stacked bar chart representation (by the type of drug eluted and stent material), a tree map representation (based on  maximum stent length and maximum stent diameter), a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain (based on several relevant parameters (such as year of establishment, company size, number of products offered and location of headquarters)) and a grid representation (based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters).
  • An insightful company competitiveness analysis of cardiovascular drug eluting stent developers, taking into consideration various relevant parameters, such as year of experience and portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness).
  • Elaborate profiles of various prominent players that are currently engaged in developing / manufacturing drug eluting stents employed for the treatment of cardiovascular disorders, featuring a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio), recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted related to cardiovascular drug eluting stents, based on various parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), patent benchmarking analysis and a detailed patent valuation analysis.
  • An insightful case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software). It also features a list of developers, along with details on their year of establishment, company size and location of headquarters. 
  • An elaborate analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of cardiac stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of patients suffering from cardiovascular disorders that can be treated using cardiovascular drug eluting stents and average price of such stents across various geographies.

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for coronary drug eluting stent market during forecast period. Based on several parameters, such as annual cases reported for cardiovascular disorders, percutaneous coronary interventions performed (in terms of number of patients) to treat such disorders, and average price for associated cardiac stent across various geographical regions, we have provided an informed estimate on the evolution of the market for the forecast period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity related to coronary drug eluting stent market across type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of cardiac stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

This image provides information about current and future demand for cardiovascular drug eluting stents. Considering the growing innovation related to stent materials and various drug combinations that can be employed to manufacture drug eluting stents, the demand for such devices is anticipated to rise in the future This image provides information on the current and future market trends and potential growth of Novel Cardiovascular Drug Delivery Market. In fact, we anticipate the overall market to grow at an annualized rate of 9.5% in the coming decade; the opportunity is likely to be well distributed by type of drug eluted and stent material  

The opinions and insights presented in the market report were influenced by discussions held with multiple stakeholders in coronary drug eluting stent market. The market research report features detailed transcripts of interviews held with several industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are drug eluting stents?

Answer: Drug eluting stents are drug coated stents used in interventional cardiology industry. They are coated with a polymer carrying an antiproliferative drug and have demonstrated reduction / prevention of in-stent restenosis.

Question 2: What is the market size for coronary drug eluting stents?

Answer: The coronary drug eluting stent market size is estimated to be worth $3.8 billion in 2022.

Question 3: What is the projected market growth of the coronary drug eluting stent market?

Answer: The coronary drug eluting stent market is expected to grow at compounded annual growth rate (CAGR) of 9.26% during the forecast period.

Question 4: Who is the leading manufacturer of coronary drug eluting stent?

Answer: Examples of key companies engaged in coronary drug eluting stent market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alvimedica, B. Braun, Boston Scientific, Cook Medical, Eurocor Scientific, Lepu Medical, Medtronic, Meril, Relisys and Sahajanand Medical Technologies.

Question 5: How many patents related to the coronary drug eluting stent and associated technologies have been filed / granted till date?

Answer: Till date, over 900 patents related to the coronary drug eluting stent have been filed / granted.

Question 6: How many products are marketed by companies engaged in the coronary drug eluting stent market?

Answer: Presently, more than 90 products are marketed by companies engaged in the coronary drug eluting stent market.

Question 7: Which region is the hub for companies engaged in the coronary drug eluting stent market?

Answer: Asia emerged as the hub for companies engaged in the coronary drug eluting stent market, with over 35% of the players established in the region.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com